Compare Aegon Ltd. (AEG) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Charles River Laboratories Intl. Inc — how do they compare? Aegon Ltd. trades at $9.41 (market cap $14.01B), while Charles River Laboratories Intl. Inc trades at $286.31 (market cap $13.46B). The key difference: Aegon Ltd. and Charles River Laboratories Intl. Inc are close in size by market cap, and Aegon Ltd. pays a 4.94% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AEG | CRL | |
|---|---|---|
Market Cap | $14.01B | $13.46B |
Sector | Financials | Health |
52-Week High | $9.53 | $282.00 |
52-Week Low | $6.79 | $145.57 |
Enterprise Value | $15.16B | $16.30B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.
AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
